Page 34 - MemoriaCIBER2019-ENG

34 CIBER Annual report 2019
Platforms: NANBIOSIS ICTS
Coordinator: Jaume Veciana Miró
After the update of the National ICTS (Singular Scientific and Technological Infrastructure) Map at the end of 2018 and the incorporation of BIONAND as a new node of NANBIOSIS, during 2019 we have worked on the integration of said node within the infrastructure. This includes the preparation of a new agreement between the three institutions to regulate, among other aspects, the operation of the ICTS, the incorporation of Nanoimaging Unit 28 and the chan- ge in the members of the Coordination Committee.
The promotion of groundbreaking biomedical solutions has been a priority for NANBIOSIS throughout this year. These solutions make available to researchers and companies the integrated expertise of the NANBIOSIS units. The cascade characterisation of nanomedicines and other cascades will be reinforced thanks to the launch of the European project SAFE-N-MEDTECH (H2020) whose objective is to create an open access platform based on online tools for companies and reference laboratories, to interconnect skills, knowledge, networks and services for the development, testing, evaluation, scaling, and exploitation of nanotechnology-based diagnostic and medical devices in the market. In the project, 27 other partners participate in addition to CIBER, and it also has a broad participation from the NANBIOSIS units and its organizational structure. In addition, projects already underway where NANBIOSIS units participate have also been continued, such as: the Biotapes project (Collaboration Challenges), the European DRIVE Project (H2020- NMBP) and the European POSITION-II project (H2020-ECSEL-2017).
In addition, NANBIOSIS is funded by the ProNanbiosis II project (Strategic promotion and Coordinated Management of Nanbiosis. SAF2017-90810-REDI) from the Dynamization Actions “Excellence Networks” call 2017, which allows hiring a person for the daily management of NANBIOSIS as an ICTS as well as for the updating of the website and commu- nication via social networks. This year, 285 requests for the services of the CIBER-BBN platforms were handled (69% from external users, of which 11% were companies and the rest were research groups from public bodies). Additio- nally, this project has allowed to continue with the development of the actions foreseen in the NANBIOSIS Marketing Plan, such as dissemination through the website and social networks, as well as the organisation of a training and internal dissemination session especially aimed at the technical staff from the units. This was attended by more than 30 people with very positive results as reflected in the satisfaction surveys.
The participation of NANBIOSIS in international organisations and its collaboration with national companies, foun- dations and public research organizations continues to be important. We have participated in the following events: Nanomed Europe Conference, NME19 (Portugal), BioNanoNet Annual Meeting and Austrian Microfluidics initiative (Salzburg, Austria), and the 12th Annual Conference of Biomedical Research Technology Platforms (Madrid). Among other activities, the collaborative approach to other ICTS stands out, such as the Alba Synchrotron and the ICTS OmicsTech. In addition, NANBIOSIS actively participates in the MATERPLAT Platform as well as in actions that come from the NANOMED-SPAIN Nanomedicine Platform.
A session dedicated to related infrastructures was held at the CIBER-BBN 2019 Annual Conference and the fourth meeting of the Scientific Advisory Committee of NANBIOSIS also took place.
For more information please visit: https://www.youtube.com/watch?v=vezgov-kc0g